Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study

The efficacy of anti-programmed death-1 (PD-1) monotherapy for advanced melanoma has been established, but it is unknown to what extent patients benefit in the real world. In this observational study with nationwide population-based data from the Dutch Melanoma Treatment Registry, we analyzed real-world outcomes of first-line anti-PD-1 monotherapy in advanced melanoma patients diagnosed in 2015 to 2016. Overall survival (OS) was estimated with the Kaplan-Meier method. Competing risks analysis was used to estimate probabilities for second-line treatment, with death as competing risk. With a Cox model, the association of factors with OS was estimated. Patients who received anti-PD-1 monotherapy (n=550) had a median age of 65 years and 502 (95%) patients had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1, 383 (70%) had normal lactate dehydrogenase (LDH), 370 (67%) had stage IV-M1c disease, and in 441 (81%), brain metastases were absent. The median OS was 24 months [95% confidence interval (CI): 20-30 mo]. The median OS of patients normally eligible for phase III trial participation was 31 months (95% CI: 23-not estimable). The BRAF mutation was associated with superior OS. ECOG PS of ≥1, symptomatic brain metastases, and liver metastases were associated with inferior OS and, together with elevated LDH, with death before second-line treatment. Patients with a complete response had a 2-year OS probability from first reported complete response o...
Source: Journal of Immunotherapy - Category: Allergy & Immunology Tags: Clinical Studies Source Type: research

Related Links:

Cancer Res. 2021 Sep 13:canres.CAN-21-0164-A.2021. doi: 10.1158/0008-5472.CAN-21-0164. Online ahead of print.ABSTRACTDespite impressive advances in melanoma-directed immunotherapies, resistance is common and many patients still succumb to metastatic disease. In this context, harnessing natural killer (NK) cells, which have thus far been sidelined in the development of melanoma immunotherapy, could provide therapeutic benefits for cancer treatment. To identify molecular determinants of NK cell-mediated melanoma killing (NKmK), we quantified NK cell cytotoxicity against a panel of genetically diverse melanoma cell lines and ...
Source: Cell Research - Category: Cytology Authors: Source Type: research
We present a case of grade 4 AIHA due to nivolumab (PD1-inhibitor) treatment in a patient with melanoma for adjuvant setting after surgery and the safeness of subsequent treatment with ipilimumab (anti-CTLA4). After the remission of AIHA with steroids, ipilimumab was started with the rationale of its different mechanism of action. Fortunately, AIHA did not recur. The mechanism by which checkpoint inhibitors cause AIHA is likely by augmenting or redirecting immune surveillance, especially by activating pre-existing red blood cell autoantibodies, but further studies must be done. To our knowledge, this is the first case publ...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
An experimental PET radiotracer can predict whether patients will respond earl...Read more on AuntMinnie.comRelated Reading: PET identifies early responders to liver cancer treatment Second-look PET/CT catches cancer spread FDG-PET/CT aids in melanoma treatment assessment New PET tracer could aid melanoma detection MRI holds promise for immunotherapy but needs more research
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Drug Deliv. 2021 Dec;28(1):1849-1860. doi: 10.1080/10717544.2021.1971797.ABSTRACTMelanoma is one of the most common malignant tumors. The anti-PD-1 antibody is used for the treatment of metastatic melanoma. Treatment success is only 35-40% and a range of immune-related adverse reactions can occur. Combination of anti-PD1 antibody therapy with other oncology therapies has been attempted. Herein, we assessed whether chlorogenic acid liposomes modified with sialic acid (CA-SAL) combined with anti-PD1 antibody treatment was efficacious as immunotherapy for melanoma. CA-SAL liposomes were prepared and characterized. In a mouse ...
Source: Drug Delivery - Category: Drugs & Pharmacology Authors: Source Type: research
In this study, we utilize data from the Cancer Cell Line Encyclopedia (CCLE), including 62 samples, to examine features of gene expression (19K+) and copy number (20K+) in the melanoma cell lines. We perform a clustering analysis on the feature set to assess genetically similarity among the cell lines. We then discover which specific genes and combinations thereof maximize cluster density. We design a feature selection approach for high-dimensional datasets that integrates multiple disparate machine learning techniques into one cohesive pipeline. Our approach provides a small subset of genes that can accurately distinguish...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
CONCLUSION: Herein, we reported the status of HRD using a cancer-panel for various solid tumor patients in routine clinical practice and demonstrated that HRD as a single biomarker was not sufficient to predict efficacy of ICIs in solid tumor patients.PMID:34510272 | DOI:10.1007/s00432-021-03781-6
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Source Type: research
i Yann Cheli The immune system is known to help fight cancers. Ten years ago, the first immune checkpoint inhibitor targeting CTLA4 was approved by the FDA to treat patients with metastatic melanoma. Since then, immune checkpoint therapies have revolutionized the field of oncology and the treatment of cancer patients. Numerous immune checkpoint inhibitors have been developed and tested, alone or in combination with other treatments, in melanoma and other cancers, with overall clear benefits to patient outcomes. However, many patients fail to respond or develop resistance to these treatments. It is therefore essential...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Tidsskr Nor Laegeforen. 2021 Aug 18;141(2021-12). doi: 10.4045/tidsskr.20.0982. Print 2021 Sep 7.ABSTRACTBACKGROUND: Immunotherapy is used to treat several cancer types. As it is a relatively new type of treatment, knowledge of optimal handling of rare side effects is sparse.CASE PRESENTATION: A woman in her early eighties with inoperable metastases from malignant melanoma was given immunotherapy. Five weeks after the first dose of nivolumab 480 mg she was admitted to the hospital with symptoms of coronary artery disease. On suspicion of side effects from nivolumab, she was given prednisolone 80 mg daily. MRI of the heart ...
Source: Tidsskrift for den Norske Laegeforening - Category: General Medicine Authors: Source Type: research
Radiotherapy is a mainstay of efficient treatment of brain metastases from solid tumors. Immunotherapy has improved the survival of metastatic cancer patients across many tumor types. However, targeted therapy is a feasible alternative for patients unable to continue immunotherapy or with poor outcomes of immunotherapy. The combination of radiotherapy and targeted therapy for the treatment of brain metastases has a strong theoretical underpinning, but data on the efficacy and safety of this combination is still limited. A systematic search of PubMed, Embase, Web of Science and the Cochrane library database was conducted. E...
Source: Melanoma Research - Category: Cancer & Oncology Tags: Review Articles Source Type: research
Merkel-cell carcinoma (MCC) is a rare and extremely aggressive nonmelanocytic cutaneous neuroendocrine carcinoma. Historically, it has been associated with limited therapy options and poor prognosis. While its incidence has been rising over the last two decades, recent discoveries and a better understanding of its pathogenesis, viral association and immunologic features have allowed for the emergence of new therapies. Surgical excision with or without radiotherapy remains the first-line therapy for primary lesions without evidence of metastatic disease. The majority of MCC cases are regrettably diagnosed at advanced stages...
Source: Melanoma Research - Category: Cancer & Oncology Tags: Review Articles Source Type: research
More News: Allergy & Immunology | Brain | Cancer & Oncology | Immunotherapy | Liver | Melanoma | Netherlands Health | Neurology | Skin Cancer | Study | Urology & Nephrology